Sumitomo Mitsui Trust Group Inc. Has $16.45 Million Stake in DaVita Inc. (NYSE:DVA)

Sumitomo Mitsui Trust Group Inc. lowered its holdings in DaVita Inc. (NYSE:DVA) by 12.8% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 109,989 shares of the company’s stock after selling 16,082 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned 0.13% of DaVita worth $16,449,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Transcendent Capital Group LLC acquired a new stake in shares of DaVita during the 3rd quarter worth approximately $25,000. Blue Trust Inc. lifted its position in shares of DaVita by 56.4% during the 3rd quarter. Blue Trust Inc. now owns 330 shares of the company’s stock worth $54,000 after buying an additional 119 shares during the period. Quarry LP bought a new position in DaVita in the 3rd quarter valued at $60,000. Versant Capital Management Inc raised its position in DaVita by 58.7% in the 4th quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock valued at $68,000 after purchasing an additional 169 shares during the last quarter. Finally, Livforsakringsbolaget Skandia Omsesidigt raised its position in DaVita by 295.9% in the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 669 shares of the company’s stock valued at $110,000 after purchasing an additional 500 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Stock Down 1.0 %

Shares of DaVita stock opened at $171.96 on Thursday. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. DaVita Inc. has a 12 month low of $111.10 and a 12 month high of $179.60. The business has a fifty day simple moving average of $161.15 and a 200 day simple moving average of $157.11. The stock has a market cap of $14.10 billion, a PE ratio of 18.55, a price-to-earnings-growth ratio of 0.84 and a beta of 0.94.

Analyst Ratings Changes

Separately, Barclays boosted their target price on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $161.80.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.